MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on January 17, 2008; DOI: 10.1124/mol.107.041251


0026-895X/08/7304-1309-1318$20.00
Mol Pharmacol 73:1309-1318, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041251v1
73/4/1309    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kim, B. H.
Right arrow Articles by Kim, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, B. H.
Right arrow Articles by Kim, Y.

Benzoxathiole Derivative Blocks Lipopolysaccharide-Induced Nuclear Factor-{kappa}B Activation and Nuclear Factor-{kappa}B-Regulated Gene Transcription through Inactivating Inhibitory {kappa}B Kinase β

Byung Hak Kim, Eunmiri Roh, Hwa Young Lee, In-Jeong Lee, Byeongwoo Ahn, Sang-Hun Jung, Heesoon Lee, Sang-Bae Han, and Youngsoo Kim

College of Pharmacy (B.H.K., E.R., H.L., S.-B.H., Y.K.), College of Veterinary Medicine (B.A.), and Research Center for Bioresource and Health (H.Y.L., I.-J.L.), Chungbuk National University, Cheongju, Korea; and College of Pharmacy, Chungnam National University, Daejeon, Korea (S.-H.J.)

Benzoxathiole derivatives have been used in the treatment of acne and have shown cytostatic, antipsoriatic, and antibacterial properties. However, little is known about the molecular basis for these pharmacological properties, although nuclear factor (NF)-{kappa}B activation is closely linked to inflammation and cell proliferation. Here, we demonstrate that the novel small-molecule benzoxathiole 6,6-dimethyl-2-(phenylimino)-6,7-dihydro-5H-benzo-[1,3]oxathiol-4-one (BOT-64) inhibits NF-{kappa}B activation with an IC50 value of 1 µM by blocking inhibitory {kappa}B(I{kappa}B) kinase β (IKKβ), and suppresses NF-{kappa}B-regulated expression of inflammatory genes in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages. BOT-64 inhibits IKKβ-mediated I{kappa}B{alpha} phosphorylation in LPS-activated macrophages, resulting in sequential prevention of downstream events, including proteolytic degradation of I{kappa}B{alpha}, DNA binding ability, and transcriptional activity of NF-{kappa}B. BOT-64 inhibits LPS-inducible IKKβ activity in the cells and catalytic activity of highly purified IKKβ. Moreover, the effect of BOT-64 on cell-free IKKβ was abolished by substitution of Ser-177 and Ser-181 residues in the activation loop of IKKβ to glutamic acid residues, indicating a direct interaction site of benzoxathiole. BOT-64 attenuates NF-{kappa}B-regulated expression of inflammatory genes such as inducible nitric-oxide synthase, cyclooxygenase-2, tumor necrosis factor-{alpha}, interleukin (IL)-1β, and IL-6 in LPS-activated or expression vector IKKβ-transfected macrophages. Furthermore, BOT-64 dose-dependently increases the survival rates of endotoxin LPS-shocked mice.


Received August 26, 2007; accepted January 17, 2008

Address correspondence to: Dr. Youngsoo Kim, College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea. E-mail: youngsoo{at}chungbuk.ac.kr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics